Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 47335-321

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 47335-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)

Chemical structure diagram of Memantine Hydrochloride showing the molecular framework with labeled functional groups NH2 and CH3, representing the active ingredient memantine hydrochloride.*

FDA Label Image

Spl-memantine-figure1 (Spl Memantine Figure1)

A line graph depicting the mean change from baseline in ADCS-ADL score over 28 weeks of treatment comparing Memantine Hydrochloride and placebo. The y-axis shows score change with clinical improvement above zero and clinical decline below zero, while the x-axis shows weeks of treatment from 0 to 28. Memantine shows less decline in scores compared to placebo over time.*

FDA Label Image

Spl-memantine-figure2 (Spl Memantine Figure2)

A cumulative percentage curve chart comparing patients completing 28 weeks of double-blind treatment with placebo and Memantine Hydrochloride. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. The graph demonstrates differences between placebo and Memantine Hydrochloride groups over the change in ADCS-ADL scores.*

FDA Label Image

Spl-memantine-figure3 (Spl Memantine Figure3)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride and placebo groups. The y-axis shows the mean change (± SEM), and the x-axis shows weeks of treatment. The graph includes labels for clinical improvement and clinical decline, indicating changes in patient scores over time.*

FDA Label Image

Spl-memantine-figure4 (Spl Memantine Figure4)

A line graph showing the cumulative percentage of patients completing 28 weeks of double-blind treatment, comparing placebo and Memantine Hydrochloride groups. The x-axis represents SIB change from baseline, and the y-axis shows cumulative percentage of patients, illustrating patient response differences between treatments.*

FDA Label Image

Spl-memantine-figure5 (Spl Memantine Figure5)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents weeks of treatment and the y-axis shows mean change with error bars. Two lines illustrate clinical improvement and decline trends for both treatment groups.*

FDA Label Image

Spl-memantine-figure6 (Spl Memantine Figure6)

A cumulative percentage line graph comparing patients treated with Memantine Hydrochloride/Donepezil to those with Placebo/Donepezil over 24 weeks, showing changes from baseline in ADCS-ADL scores. The x-axis represents ADCS-ADL change from baseline; the y-axis shows cumulative percentage of patients.*

FDA Label Image

Spl-memantine-figure7 (Spl Memantine Figure7)

Line graph showing the mean change from baseline in SIB score over 24 weeks of treatment comparing Memantine Hydrochloride/Donepezil and Placebo/Donepezil. The graph plots weeks of treatment on the x-axis and mean change in SIB score on the y-axis, illustrating clinical improvement with Memantine Hydrochloride/Donepezil and clinical decline with Placebo/Donepezil.*

FDA Label Image

Spl-memantine-figure8 (Spl Memantine Figure8)

This chart depicts the cumulative percentage of patients completing 24 weeks of double-blind treatment, showing changes from baseline in SIB (Severe Impairment Battery) scores. It compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with the x-axis representing SIB change and the y-axis showing cumulative percentage of patients.*

FDA Label Image

Spl-memantine-label-10mg (Spl Memantine Label 10mg)

Memantine Hydrochloride Tablets 10 mg film-coated tablets label showing a package of 60 tablets. The label includes the NDC 47335-322-86 and the manufacturer Sun Pharmaceutical Industries, Inc. The design features a green panel highlighting the 10 mg strength and the label notes Rx only.*

FDA Label Image

Spl-memantine-label-5mg (Spl Memantine Label 5mg)

Label for Memantine Hydrochloride Tablets 5 mg film-coated tablets. The label indicates it is a prescription drug with a package size of 60 tablets. The labeler is Sun Pharmaceutical Industries, Inc. The label includes a barcode and instructions to open for full labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.